Ask AI
ProCE Banner Activity

CLL Challenge: Expert Office Hours Social Media Forum

Clinical Thought

Experts answer questions related to the program, “CLL Challenge! Interrogating the Latest Evidence on Patient Priorities and Novel Targeted Therapies.” This social media forum provides learners with ongoing access to faculty throughout the certified life of this program.

Released: November 06, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with CLL Society.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, and Lilly.

AstraZeneca

BeOne Medicines

Lilly

Partners

CLL Society

ProCE Banner

Target Audience

This educational activity is intended for hematologists, oncologists, nurse practitioners, physician associates, nurses, pharmacists, and other healthcare professionals who care for individuals with CLL/SLL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Support patient engagement in the management of CLL/SLL through effective shared decision-making and communication strategies

  • Compare the mechanisms of action and clinical rationales for novel targeted therapies that are approved vs under investigation for management of CLL/SLL

  • Recommend individualized treatment sequences leveraging novel targeted and/or cellular therapies for eligible patients with CLL/SLL in alignment with patient preferences, clinical evidence, and expert recommendations

  • Assess the clinical implications of emerging efficacy and safety data for novel targeted and cellular therapies on treatment sequencing in CLL/SLL

  • Apply best practices for biomarker testing before treatment initiation and at disease progression to guide optimal therapy selection and sequencing in patients with CLL/SLL

Financial Disclosures

Primary Author

Nitin Jain, MD: researcher: AbbVie, Adaptive, ADC Therapeutics, Ascentage, AstraZeneca, BeOne, Bioheng, Bristol Myers Squibb, Carna, Cellectis, Fate, Genentech, Kisoji, Kite/Gilead, Lilly, Mingsight, Newave, Novartis, Pharmacyclics, Precision, Sana, Takeda, Triarm, Ubix; consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, Autolus, BeOne, Bristol Myers Squibb, Cellectis, Genentech, Janssen, Kite/Gilead, Lilly, Novalgen, Nurix, Pharmacyclics, SERB.

Brian Koffman, MDCM (retired), MS Ed: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Genmab, Invyvid, Johnson & Johnson; independent contractor: AbbVie, BeOne, Biomea Fusion, Bristol Myers Squibb, Johnson & Johnson, Lilly; individual publicly traded stock/stock options: AbbVie, AstraZeneca, Biomea Fusion, Bristol Myers Squibb, Invyvid, Johnson & Johnson, Merck, Nurix, Pfizer, Vincerex.

Meghan C. Thompson, MD: consultant/advisor: AbbVie, AstraZeneca, BeiGene/BeOne, Genentech, Loxo Oncology at Lilly; other material or financial support: Dava Oncology; researcher (paid to institution): AbbVie, Adaptive, AstraZeneca, BeiGene/BeOne, GenMab, Nurix, Genentech, Loxo Oncology at Lilly.

Jennifer Woyach, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Genentech, Loxo@Lilly, Merck, Newave; researcher: AbbVie, Johnson & Johnson, Loxo@Lilly, Merck, Schrödinger.